AFRESA™ Suppresses Endogenous Glucose Production Earlier Than a Rapid-Acting Analog (Lispro) and Inhaled Exubera®

被引：0
|
作者：
Potocka, Elizabeth
Hovorka, Roman
Baughman, Robert A.
Umpleby, Margot
Diaz, Mella Louise M.
Chen, Ru
Boss, Anders H.
Richardson, Peter C.
机构：
来源：
DIABETES | 2009年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A61 / A61
页数：1
相关论文
共 19 条
  • [1] Technosphere insulin suppresses endogenous glucose production earlier than a rapid-acting analogue (lispro) and an inhaled insulin (Exubera®)
    Potocka, E.
    Hovorka, R.
    Baughman, R.
    Umpleby, M.
    Diaz, M.
    Chen, R.
    Cassidy, J.
    Boss, A.
    Richardson, P.
    [J]. DIABETOLOGIA, 2009, 52 : S374 - S374
  • [2] Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog
    Grant, Marshall L.
    Pompilio, Frank
    Sharma, Gaurav
    Krueger, John A.
    Kendall, David M.
    Zaveri, Nadia
    [J]. DIABETES, 2019, 68
  • [3] Insulin lispro (Humalog®, rDNA origin), a rapid-acting mealtime human insulin analog.
    Anderson, JH
    Chance, RE
    DiMarchi, RD
    Frank, BH
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U892 - U892
  • [4] Patient Reported Outcomes in Adults with Type 1 Diabetes Using Mealtime AFRESA™ (Inhaled Technosphere® Insulin) or Rapid-Acting Insulin with Basal Insulin
    Rubin, Richard R.
    Peyrot, Mark
    [J]. DIABETES, 2009, 58 : A484 - A484
  • [5] Fast acting insulin analog (LISPRO) improves glucose tolerance of NIDDM by inhibiting hepatic glucose production
    Bruttomesso, D
    Pianta, A
    Valerio, A
    Tadiotto, F
    Lavagnini, T
    DelPrato, S
    [J]. DIABETES, 1996, 45 : 513 - 513
  • [6] Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus
    Levin, Philip
    Hoogwerf, Byron J.
    Snell-Bergeon, Janet
    Vigers, Tim
    Pyle, Laura
    Bromberger, Lee
    [J]. ENDOCRINE PRACTICE, 2021, 27 (05) : 449 - 454
  • [7] Comparative Efficacy and Safety of AFRESA™ and a Rapid-Acting Analog Both Given with Glargine in Subjects with T1DM in a 52-Week Study
    Bergenstal, Richard M.
    Kapsner, Patricia L.
    Rendell, Marc S.
    Boss, Anders H.
    Howard, Campbell P.
    Chang, Ping-Chung
    Richardson, Peter C.
    [J]. DIABETES, 2009, 58 : A128 - A128
  • [8] Use of rapid-acting insulin analog as the baseline infusion during glucose clamping improves pharmacokinetic evaluation
    Cassidy, James
    Baughman, Robert
    Tonelli, George
    Boss, Anders
    Hernandez, Bobbie
    Schwartz, Sherwyn
    [J]. DIABETES, 2007, 56 : A159 - A160
  • [9] TECHNOSPHERE INSULIN PROVIDES BETTER EARLY POSTPRANDIAL GLUCOSE CONTROL THAN SUBCUTANEOUS RAPID-ACTING ANALOGUE
    Grant, M.
    Pompilio, F.
    Sharma, G.
    Zaveri, N.
    Krueger, J.
    Kendall, D.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A44 - A45
  • [10] Rapid-Acting Insulin Analog Rather Than Short-Acting Insulin, Can Decrease Wound Infection Risk With Controlling Blood Glucose Drifting in the Surgical Diabetic Patients
    Ueno, Hiroki
    Hosoi, Masayuki
    Yoshida, Yoko
    Yakushizi, Yosuke
    Hosokawa, Yuki
    Tanaka, Nagaaki
    Yamagami, Keiko
    Kawasaki, Isao
    Hiura, Yoshikazu
    [J]. DIABETES, 2012, 61 : A552 - A552
12